Brightlands Venture Partners invests in Noah Labs in private funding round

• Brightlands Venture Partners invested in Noah Labs, a Berlin-founded, Boston-headquartered health technology company focused on voice-based heart failure monitoring.
• Funding backs the US clinical and regulatory program, anchored by the VOICE-HF pivotal trial, alongside European commercial expansion.
• Noah Labs’ Vox analyzes short smartphone voice recordings to flag worsening heart failure before symptoms, aiming to reduce hospital admissions.
• In the TIM-HF3 Voice study of 105 outpatients, Vox detected 84% of worsening events a median 29 days early.
• Vox holds FDA Breakthrough Device Designation; the program targets an FDA De Novo submission.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Brightlands Venture Partners BV published the original content used to generate this news brief on October 08, 2026, and is solely responsible for the information contained therein.